Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Xenon Pharmaceuticals Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1.8
0.31
6.83
32.2
18.4
9.43
0
0
7.5
Research and development
19.8
25.6
23.6
38.8
50.5
75.5
106
168
210
301
General and administrative
6.79
7.31
8.41
10.8
12.9
22
32.8
46.5
68.9
79.6
Operating expenses
26.6
32.9
38
49.6
63.5
97.4
139
214
279
381
Operating income
-24.8
-32.6
-38
-42.8
-31.3
-79
-129
-214
-279
-373
Interest expense
1.39
1.43
0.48
Interest income
0.5
0.48
1.22
2.35
2.28
0.47
8.71
27.6
41.9
26.8
Other non-operating income
2.21
0.11
3.89
31.4
40.9
28.2
Pre-tax income
-34.5
-41.6
-29.1
-78.9
-125
-183
-238
-345
Income tax
-0.02
-0.02
-0.26
-0.01
0.12
-0.29
-4.09
1.02
Net income
-23
-30.7
-34.5
-41.6
-28.8
-78.9
-125
-182
-234
-346
EBITDA
-24
-31.9
-37.5
-42.4
-30.7
-78.1
-128
-212
-277
-371
EPS, basic
-1.48
-1.71
-1.63
-1.54
-0.81
-1.77
-2.06
-2.73
-3.01
-4.36
EPS, diluted
-1.48
-1.72
-1.63
-1.54
-0.81
-1.77
-2.06
-2.73
-3.01
-4.36
Shares, basic (weighted)
15.5
18
19.4
25.9
34.5
43.6
60.5
66.9
77.9
79.3
Shares, diluted (weighted)
15.5
18
19.4
25.9
34.5
43.6
60.5
66.9
77.9
79.3
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
17.1
20.5
67.8
24.8
45
176
57.2
149
143
199
Short-term investments
47.1
23.2
51.6
117
132
376
535
489
484
350
Receivables
0.2
0.44
0.15
0.81
1.82
2.77
0.99
0.87
1.47
Other current assets
1.33
0.72
1.88
2.7
2.96
4.48
7.23
6.01
6.89
10.4
Total current assets
65.7
44.8
121
145
182
559
600
645
635
561
Property, plant and equipment
1.4
1.07
0.99
1.66
3.55
4.47
6.5
9.65
10.3
8.72
Lease right-of-use assets
0.93
3.33
8.06
10.4
9.19
7.94
6.63
Long-term investments
0
129
293
127
37.2
Total assets
67.5
46.1
122
148
189
572
754
965
798
633
Accounts payable
1.46
1.25
0.67
2.47
3.04
3.82
8.49
8.6
5.07
3.89
Accrued liabilities
0.87
1.02
1.73
2.89
2.86
5.94
5.82
7.43
9.93
36.4
Deferred revenue
29.7
3.64
Short-term debt
0.7
4.65
Total current liabilities
3.59
4.08
4.12
43.4
14.8
14.3
22.7
27.3
35.6
41.8
Long-term debt
6.1
15
10.9
Lease liabilities
0.74
3.05
7.65
9.95
9.6
7.65
6.41
Other non-current liabilities
0
3.2
Total liabilities
3.59
10.2
19.1
55.7
17.8
22
32.6
36.9
43.2
51.4
Total debt
6.8
15
15.5
Paid-in capital
34.3
36.5
38.5
40.6
45.4
117
142
157
199
228
Retained earnings
-143
-173
-208
-250
-278
-357
-483
-665
-899
-1,245
Other comprehensive income
-0.99
-0.99
-0.99
-0.99
-0.99
-0.99
-3
-0.08
-1.61
0.34
Shareholders' equity
63.9
35.9
103
92
171
550
721
928
755
582
Total equity
63.9
35.9
103
92
171
550
721
928
755
582
Total liabilities and equity
67.5
46.1
122
148
189
572
754
965
798
633
Shares outstanding
17.9
18
25.8
28.1
35
51.6
62.6
75.4
76.4
80
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-23
-30.7
-34.5
-41.6
-28.8
-78.9
-125
-182
-234
-346
Depreciation and amortization
0.86
0.65
0.59
0.43
0.64
0.91
1.41
2.06
2.56
2.54
Stock-based compensation
2.16
2.24
2.63
2.92
5.68
10
20.4
32.4
50.7
53.7
Deferred income tax
-0.11
-0.13
-0.29
0.06
-0.04
-0.29
-8.86
-3.2
Change in receivables
0.12
-0.23
0.28
-0.65
-1.03
-0.46
1.76
0.13
-0.61
Change in payables
0.48
-0
0.78
4.54
2.02
2.97
8.06
3.93
8.53
5.51
Cash from operations
-19.6
-28.7
-34.7
-4.71
-48.1
-69.5
-101
-151
-181
-279
Capital expenditures
-0.28
-0.32
-0.51
-1.24
-2.64
-2.05
-2.89
-5.62
-3.08
-0.8
Purchases of investments
-47.6
-28
-77
-140
-229
-389
-551
-794
-532
-356
Sales and maturities of investments
52.6
48.5
75.5
215
145
261
688
700
574
Cash from investing
-47.8
24.3
-29
-66.2
-16.8
-247
-293
-111
165
218
Stock issued
23.8
103
27.4
102
0.71
0.04
0.05
4.96
Cash from financing
24
7.07
112
27.5
85.8
448
278
354
12.1
117
Exchange rate effect
-0.61
0.41
-0.59
-0.59
-2.48
0.38
-1.67
0.46
Net change in cash
-41.6
3.39
47.3
-43
20.3
131
-118
91.4
-5.93
56.5
Free cash flow
-19.8
-29
-35.2
-5.95
-50.8
-71.6
-104
-157
-184
-280
Interest paid
0.56
0.92
0.34
0
0
Income taxes paid
8.42
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $36.94 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-32.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-31.6%
Net income / average total assets.
Return on invested capital (ROIC)
-31.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue CAGR, 3y
-7.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-25.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-22.9%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-6.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
27.7%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-20.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-5.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
27.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
9.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
18.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
21.0x
Current assets / current liabilities.
Quick ratio
20.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
20.7x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
FCF per share
-$3.40
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$3.39
Cash from operations / diluted weighted shares.
Book value per share
$12.84
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
2.88x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.88x
Market cap / tangible book value, when positive.
FCF yield
-9.5%
Free cash flow / market cap.
Earnings yield
-11.4%
Net income / market cap (the inverse of P/E).
What was Xenon Pharmaceuticals Inc.'s revenue in fiscal 2025?
Xenon Pharmaceuticals Inc. reported revenue of $7.5M for fiscal 2025.
Was Xenon Pharmaceuticals Inc. profitable in fiscal 2025?
No. It reported a net loss of $345.9M.
How much free cash flow did Xenon Pharmaceuticals Inc. generate in fiscal 2025?
Cash from operations of $279.1M minus capital expenditures of $799.0K left free cash flow of -$279.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.